This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Intern Med. 2001;161:767.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Hereditary hemorrhagic telangiectasia (HHT [Osler-Rendu-Weber disease]) is a dominantly inherited disease characterized by multiple telangiectatic lesions or arteriovenous malformations that may rupture and bleed. Symptoms vary according to the location of the lesions, but the skin, nasal mucosa, gastrointestinal tract mucosa, and pulmonary, cerebral, or hepatic circulation are commonly affected.¹ The prevalence of HHT in Europe is 14 to 16 persons per 100 000 and may be rising. Epistaxis is both an early and very common manifestation of HHT affecting most patients and is often recurrent, severe, and resistant to treatment.² We report a simple, safe, and efficacious treatment for recurrent severe epistaxis in HHT.

Report of a Case

A 50-year-old man presented with severe iron-deficiency anemia (hemoglobin level, 56.0 g/L). Frequent (almost daily) episodes of severe epistaxis were the cause, and the diagnosis of HHT was established by the additional findings of telangiectasia and a positive family history. Epistaxis first appeared in young adulthood . . . [Full Text of this Article]

Comment

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy of Unusually High Doses of Tranexamic Acid for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
Sabba et al.
NEJM 2001;345:926-926.
FULL TEXT